Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02781519 · ClinicalTrials.gov registry record · Phase 1

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans

A Phase 1 study of Cannabis, sponsored by Yale University.

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
1
Study location

NCT02781519 is a Phase 1 study of Cannabis that is actively recruiting participants, run by Yale University. The registered enrollment target is 100 participants, roughly in line with the 107-participant average among 24 other Cannabis trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02781519, a Phase 1 study of Cannabis, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG THC

Study Locations (1)

Connecticut

  • Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine - West Haven

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2015-06
Est. Completion 2026-12
Phase Phase 1

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT02781519

The ClinicalTrials.gov registry entry for NCT02781519 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 107-participant average among 24 other Cannabis trials with a reported enrollment target. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cannabis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02781519 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT02781519 about?

NCT02781519 is a clinical study titled "Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans". The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.

What is the current status of trial NCT02781519?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2015-06. Estimated completion is 2026-12.

What conditions does trial NCT02781519 study?

This clinical trial studies the following conditions: Cannabis.

What interventions are being tested in trial NCT02781519?

The interventions under investigation include: Placebo (DRUG), THC (DRUG).

Who is sponsoring clinical trial NCT02781519?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02781519 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cannabis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.